Last Updated: September 28, 2026

Chartwell Rx Company Profile

✉ Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for CHARTWELL RX

CHARTWELL RX has four hundred and seventy-nine approved drugs.

There are two tentative approvals on CHARTWELL RX drugs.

Summary for Chartwell Rx

US Patents:	0
Tradenames:	342
Ingredients:	324
NDAs:	479

Drugs and US Patents for Chartwell Rx

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chartwell Rx	AZITHROMYCIN	azithromycin	FOR SUSPENSION;ORAL	065488-002	May 15, 2015	AB	RX	No	No		⤷ Start Trial				⤷ Start Trial
Chartwell Rx	IRINOTECAN HYDROCHLORIDE	irinotecan hydrochloride	INJECTABLE;INJECTION	078953-002	Apr 15, 2010		DISCN	No	No		⤷ Start Trial				⤷ Start Trial
Chartwell Rx	CIMETIDINE	cimetidine	TABLET;ORAL	074100-002	Jan 31, 1995		DISCN	No	No		⤷ Start Trial				⤷ Start Trial
Chartwell Rx	DIETHYLPROPION HYDROCHLORIDE	diethylpropion hydrochloride	TABLET;ORAL	088267-001	Aug 25, 1983		DISCN	No	No		⤷ Start Trial				⤷ Start Trial
Chartwell Rx	POTASSIUM CHLORIDE	potassium chloride	TABLET, EXTENDED RELEASE;ORAL	206630-001	Mar 29, 2019		DISCN	No	No		⤷ Start Trial				⤷ Start Trial
Chartwell Rx	SPIRONOLACTONE	spironolactone	TABLET;ORAL	086809-001	Approved Prior to Jan 1, 1982		DISCN	No	No		⤷ Start Trial				⤷ Start Trial
Chartwell Rx	PREDNISOLONE SODIUM PHOSPHATE	prednisolone sodium phosphate	SOLUTION;ORAL	075988-001	May 25, 2004	AA	RX	No	No		⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for Chartwell Rx

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Chartwell Rx	MOBAN	molindone hydrochloride	TABLET;ORAL	017111-008	Approved Prior to Jan 1, 1982	3,491,093	⤷ Start Trial
Chartwell Rx	MOBAN	molindone hydrochloride	TABLET;ORAL	017111-004	Approved Prior to Jan 1, 1982	3,491,093	⤷ Start Trial
Chartwell Rx	VELTIN	clindamycin phosphate; tretinoin	GEL;TOPICAL	050803-001	Jul 16, 2010	5,690,923	⤷ Start Trial
Chartwell Rx	LIMBITROL DS	amitriptyline hydrochloride; chlordiazepoxide	TABLET;ORAL	016949-002	Approved Prior to Jan 1, 1982	4,316,897	⤷ Start Trial
Chartwell Rx	LIMBITROL	amitriptyline hydrochloride; chlordiazepoxide	TABLET;ORAL	016949-001	Approved Prior to Jan 1, 1982	4,316,897	⤷ Start Trial
Chartwell Rx	VELTIN	clindamycin phosphate; tretinoin	GEL;TOPICAL	050803-001	Jul 16, 2010	9,492,384	⤷ Start Trial
Chartwell Rx	MOBAN	molindone hydrochloride	TABLET;ORAL	017111-005	Approved Prior to Jan 1, 1982	3,491,093	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.